LUCA Science has developed a unique method to isolate and engineer functional mitochondria that can be delivered to specific disease-targeted areas. By using drug delivery and formulation technology, these mitochondria can be stored and delivered as a biopharmaceutical agent. This platform has the potential to improve and stabilize disease states by controlling mitochondrial activity, offering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional tissues and organs. LUCA Science's solutions have applications in various therapeutic areas, including immunology, respiratory, CNS, and obstetric. Founded in 2018 and based in Tokyo, Japan, the company serves customers in the healthcare sector.